- Exact Sciences (NASDAQ:EXAS) Q1 results ($M): Revenue: 90.3 (+86.6%).
- Net loss: (39.4) (-12.9%); loss/share: (0.33) (-3.1%).
- Cologuard test volume: 186K (+87%).
- 2018 Guidance: Revenue: $420M - 430M (unch); Cologuard test volume: 900K - 920K (unch).
- Q2 Guidance: Cologuard test volume: 220K - 230K.
- Shares are up 1% after hours on light volume.
Exact Sciences Q1 revenue up 87%; shares up 1% after hours
Recommended For You
More Trending News
About EXAS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EXAS | - | - |
Exact Sciences Corporation |